fingolimod hydrochloride has been researched along with mycophenolic acid in 24 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (mycophenolic acid) | Trials (mycophenolic acid) | Recent Studies (post-2010) (mycophenolic acid) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 9,029 | 1,506 | 3,772 |
| Protein | Taxonomy | fingolimod hydrochloride (IC50) | mycophenolic acid (IC50) |
|---|---|---|---|
| Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) | 0.1496 | |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | 0.014 | |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | 0.014 | |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | 0.014 | |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | 0.014 | |
| Inosine-5'-monophosphate dehydrogenase 1 | Homo sapiens (human) | 0.0772 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.011 | |
| Inosine-5'-monophosphate dehydrogenase | Cryptococcus neoformans var. neoformans JEC21 | 0.12 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (79.17) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Kelly, DA; van Mourik, ID | 1 |
| Hof, RP; Matsumoto, Y | 1 |
| Baumlin, Y; Hof, A; Hof, RP; Matsumoto, Y | 1 |
| Braun, WE | 1 |
| McDonald, RA; Nemeth, TL; Smith, JM | 1 |
| Birnbaum, F; Braunstein, S; Claas, F; Mayer, K; Reinhard, T; Reis, A; Sundmacher, R | 1 |
| Cerio, J; Gabardi, S | 1 |
| Baczkowska, T; Durlik, M | 1 |
| Felipe, CR; Garcia, R; Machado, PG; Medina-Pestana, JO; Park, SI; Schmouder, R; Skerjanec, A; Tedesco-Silva, H | 1 |
| Boira, JG; Charpentier, B; Kahan, BD; Madsen, S; Mourad, G; Mulgaonkar, S; Nashan, B; Pellet, P; Tedesco-Silva, H; Vanrenterghem, Y; Weimar, W | 1 |
| Cozzi, E; Schuurman, HJ; Smith, HT | 1 |
| Harada, T; Kanekake, H; Nishikido, M | 1 |
| Ijzermans, JN; Mol, WM; Vaessen, LM; van Besouw, NM; Weimar, W | 1 |
| Aradhye, S; Budde, K; Charpentier, B; Eisenberger, U; Eris, J; Hmissi, A; Klempnauer, J; Nashan, B; Pallardo, LM; Rostaing, L; Salvadori, M; Schena, FP | 1 |
| Cibrik, D; Esmeraldo, Rde M; Gugliuzza, KK; Kahan, BD; Lord, H; Mulgaonkar, S; Pescovitz, MD; Rajagopalan, PR; Rees, MA; Salvadori, M; Slade, JM; Tedesco-Silva, H | 1 |
| Cremer, M; Ferguson, R; Grinyó, J; Jardine, A; Juarez, F; Klinger, M; Mulgaonkar, S; Oppenheimer, F; Ostrowski, M; Preiss, R; Torres, A; Walker, R | 1 |
| Burton, JM; O'Connor, P | 1 |
| Cremer, M; Hmissi, A; Lang, P; Mayer, H; Schena, FP; Shoker, A; Sommerer, C; Szakaly, P; Tedesco-Silva, H; Yoshimura, N | 1 |
| Abdollahi, A; Domhan, S; Zeier, M | 1 |
| Lock, JF; Malinowski, M; Martus, P; Neuhaus, P; Stockmann, M | 1 |
| Abramowicz, D; Hoitsma, AJ; Proot, P; Vanrenterghem, Y; Woodle, ES | 1 |
| Lei, T; Liu, G; Peng, J; Sun, C; Wang, R; Wu, T; Xu, K; Zhang, L; Zhao, Y | 1 |
| Graves, D; Vernino, S | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
8 review(s) available for fingolimod hydrochloride and mycophenolic acid
| Article | Year |
|---|---|
Immunosuppressive drugs in paediatric liver transplantation.
Topics: Animals; Child; Child, Preschool; Cyclosporine; Drug Interactions; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Liver Transplantation; Mycophenolic Acid; Propylene Glycols; Sirolimus; Sphingosine; Tacrolimus | 2001 |
Renal transplantation: basic concepts and evolution of therapy.
Topics: Antibodies, Monoclonal; Azathioprine; Calcineurin Inhibitors; Cyclosporine; Fingolimod Hydrochloride; Glucocorticoids; Humans; Immunosuppressive Agents; Kidney Transplantation; Mycophenolic Acid; Propylene Glycols; Receptors, Interleukin-2; Sirolimus; Sphingosine; Tacrolimus | 2003 |
Current immunosuppressive agents: efficacy, side effects, and utilization.
Topics: Abatacept; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Area Under Curve; Basiliximab; Cyclosporine; Daclizumab; Drug Therapy, Combination; Drug Utilization; Everolimus; Fingolimod Hydrochloride; Graft Survival; Humans; Immunoconjugates; Immunoglobulin G; Immunosuppressive Agents; Muromonab-CD3; Mycophenolic Acid; Propylene Glycols; Recombinant Fusion Proteins; Sirolimus; Sphingosine; Tacrolimus | 2003 |
Future immunosuppressive agents in solid-organ transplantation.
Topics: Drug Approval; Drug Interactions; Drug Monitoring; Everolimus; Fingolimod Hydrochloride; Forecasting; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Mycophenolic Acid; Organ Transplantation; Propylene Glycols; Safety; Sirolimus; Sphingosine; Transplantation Immunology; Treatment Outcome | 2004 |
[Immunossupresive drugs in renal transplantation].
Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Azathioprine; Cyclosporine; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Mycophenolic Acid; Propylene Glycols; Risk Factors; Rituximab; Sirolimus; Sphingosine; Tacrolimus | 2004 |
[Molecular action mechanisms of the therapeutic agents for kidney diseases: Immunosuppressants].
Topics: Antibodies, Monoclonal; Azathioprine; Basiliximab; Cyclophosphamide; Cyclosporine; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Mycophenolic Acid; Propylene Glycols; Recombinant Fusion Proteins; Ribonucleosides; Sphingosine | 2006 |
Novel oral agents for multiple sclerosis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Isoxazoles; Leflunomide; Minocycline; Multiple Sclerosis; Mycophenolic Acid; Propylene Glycols; Pyridones; Quinolones; Sphingosine | 2007 |
Immunotherapies in neurologic disorders.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Cyclosporine; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Mitoxantrone; Mycophenolic Acid; Natalizumab; Nervous System Diseases; Peptides; Plasma Exchange; Propylene Glycols; Rituximab; Sphingosine; Tacrolimus | 2012 |
7 trial(s) available for fingolimod hydrochloride and mycophenolic acid
| Article | Year |
|---|---|
Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Cyclosporine; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Middle Aged; Mycophenolic Acid; Propylene Glycols; Sphingosine; Time Factors | 2005 |
FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
Topics: Adolescent; Adult; Aged; Biopsy; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Infections; Kidney Transplantation; Middle Aged; Mycophenolic Acid; Postoperative Complications; Propylene Glycols; Safety; Sphingosine; Time Factors; Treatment Outcome | 2005 |
FTY720 treatment of kidney transplant patients: a differential effect on B cells, naïve T cells, memory T cells and NK cells.
Topics: B-Lymphocytes; Fingolimod Hydrochloride; Granulocytes; Humans; Immunosuppressive Agents; Kidney Transplantation; Killer Cells, Natural; Leukocytes, Mononuclear; Monocytes; Mycophenolic Acid; Propylene Glycols; Receptors, CCR5; Receptors, CCR7; Receptors, Chemokine; Receptors, CXCR3; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes | 2006 |
FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia.
Topics: Adult; Australasia; Creatinine; Cyclosporine; Drug Therapy, Combination; Europe; Fingolimod Hydrochloride; Graft Survival; Histocompatibility Testing; Humans; Kidney Transplantation; Liver Function Tests; Mycophenolic Acid; Propylene Glycols; Safety; Sphingosine | 2006 |
Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.
Topics: Adult; Creatinine; Cyclosporine; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Propylene Glycols; Sphingosine | 2006 |
FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study.
Topics: Adult; Biopsy; Bradycardia; Cohort Studies; Cyclosporine; Double-Blind Method; Female; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Mycophenolic Acid; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2007 |
FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study.
Topics: Adolescent; Adult; Aged; Cyclosporine; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prognosis; Propylene Glycols; Sphingosine; Survival Rate; Tacrolimus; Young Adult | 2011 |
9 other study(ies) available for fingolimod hydrochloride and mycophenolic acid
| Article | Year |
|---|---|
Effects of mycophenolate sodium with or without FTY720 in a DA-to-Lewis rat heart transplantation model.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Mycophenolic Acid; Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Sphingosine; Time Factors; Transplantation, Homologous | 2002 |
Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model.
Topics: Animals; Drug Therapy, Combination; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Leukocyte Count; Male; Mycophenolic Acid; Myocardium; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Transplantation, Homologous | 2002 |
FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations.
Topics: Animals; Antigens, CD; Corneal Transplantation; Female; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Mycophenolic Acid; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred Lew; Sphingosine; Weight Loss | 2004 |
Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates.
Topics: Animals; Cyclophosphamide; Cyclosporine; Drug Synergism; Everolimus; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Leukocyte Count; Macaca fascicularis; Male; Methotrexate; Mycophenolic Acid; Organ Transplantation; Papio; Propylene Glycols; Sirolimus; Sphingosine | 2005 |
Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients.
Topics: Adrenergic Antagonists; Adult; Female; Fingolimod Hydrochloride; Heart Conduction System; Heart Rate; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Propylene Glycols; Sphingosine | 2007 |
Immunosuppressive therapy and post-transplant malignancy.
Topics: Azathioprine; Calcineurin Inhibitors; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mycophenolic Acid; Neoplasms; Organ Transplantation; Propylene Glycols; Protein Kinases; Sphingosine; TOR Serine-Threonine Kinases | 2009 |
Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function.
Topics: Animals; Biological Transport; Cyclosporine; Diarrhea; Everolimus; Fingolimod Hydrochloride; Glucose; Immunosuppressive Agents; Intestinal Absorption; Intestine, Large; Intestine, Small; Male; Mycophenolic Acid; Propylene Glycols; Rats; Rats, Wistar; Sirolimus; Sphingosine; Tacrolimus | 2011 |
Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.
Topics: Adoptive Transfer; Animals; CD4-Positive T-Lymphocytes; Cell Count; Cyclophosphamide; Cyclosporine; Fingolimod Hydrochloride; Forkhead Transcription Factors; Immune Tolerance; Immunity; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Isoxazoles; Leflunomide; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Mycophenolic Acid; Ovalbumin; Propylene Glycols; Sirolimus; Sphingosine; Spleen; T-Lymphocytes, Regulatory | 2012 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |